BCAX
Bicara Therapeutics Inc. Common StockHealthcare·Biotechnology
$21.75
$1.2B market cap
Revenue
$0.0M
Free Cash Flow
$-61.7M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Bioc
2-Year Price History
$21.68-7.4%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -60.2 | -60.2 | -56.2 | -37.5 | -37.6 | -0.1 | 539.8 | 1.4 | 60.7 | -99.3% | -- | -- |
| Act | 2025-Q4 | 0.0 | -41.1 | -41.1 | -37.4 | -23.9 | -24.1 | -0.2 | 414.8 | 1.7 | 55.1 | -124.5% | -- | -- |
Valuation & Metrics
Market Stats
Price$21.75
Market Cap$1.2B
Enterprise Value$653M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-5.2%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-93.6M
Free Cash Flow$-61.7M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-111.9%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares8.9M
Days to Cover21.4
Change (vs Prior)-4.6%
Need at least 2 settlement dates for chart
Employees
Headcount55
Revenue / Employee$0
Gross Profit / Employee$0
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
106.6%(+55.9% YoY)
130 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
13.3%(+9.5% YoY)
11 filers
Vanguard, iShares, SPDR
Market makers
0.0%(+0.0% YoY)
4 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $144M | $25.24 | +$6.0M | +$6.0M | -4.4% | $9.44B |
| T. Rowe Price Investment Management, Inc. | $131M | $18.32 | +$67.0M | +$131M | -1.3% | $145.22B |
| Siren, L.L.C. | $115M | $19.20 | +$11.7M | +$50.4M | +6.6% | $3.61B |
| Vestal Point Capital, LP | $108M | $14.64 | +$36.8M | +$52.8M | -0.0% | $3.58B |
| Deep Track Capital, LP | $80.8M | $19.00 | +$28.8M | +$41.0M | -1.1% | $4.85B |
| JANUS HENDERSON GROUP PLC | $66.4M | $19.71 | +$13.8M | +$39.6M | +1.2% | $209.29B |
| Red Tree Management, LLC | $63.1M | $17.42 | +$0 | +$0 | -8.2% | $112M |
| TPG GP A, LLC | $59.9M | $25.47 | +$0 | +$0 | -2.4% | $3.32B |
| BlackRock, Inc.Passive | $56.6M | $15.21 | +$6.3M | +$29.9M | -0.2% | $5.69T |
| Omega Fund Management, LLC | $47.6M | $25.03 | +$3.7M | +$3.7M | -8.9% | $163M |
| Royalty Pharma Sub-Manager, LLC | $46.7M | $18.27 | +$22.4M | +$46.7M | +14.7% | $173M |
| FMR LLC | $41.8M | $19.85 | −$24.8M | −$30.0M | -0.0% | $1.89T |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $35.3M | $19.89 | +$35.3M | +$35.3M | — | $4.04T |
| CITADEL ADVISORS LLC | $33.0M | $19.66 | +$17.6M | +$33.0M | -0.4% | $138.22B |
| FRANKLIN RESOURCES INC | $32.3M | $16.80 | +$32K | +$32.0M | -0.2% | $403.03B |
| STATE STREET CORPPassive | $28.2M | $15.98 | −$4.6M | +$20.9M | -0.2% | $2.89T |
| PRICE T ROWE ASSOCIATES INC /MD/ | $27.4M | $21.34 | −$3.6M | −$8.4M | -0.2% | $864.93B |
| Jones Hill Capital LP | $25.1M | $19.89 | +$25.1M | +$25.1M | — | $466M |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $16.5M | $15.78 | +$388K | +$6.7M | +2.3% | $1.61T |
| FIL Ltd | $13.5M | $25.47 | −$1.6M | −$6.6M | +0.2% | $128.59B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-0.25%
avg per quarter
Holders (ex-self)
-0.48%
excl. this stock
Buyers (this Q)
-0.92%
84 buyers · $0.43B in
Sellers (this Q)
-0.11%
42 sellers · $0.02B out
alpha coverage: 95% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+2.2%
how holders react when this stock falls
On quiet Qs
+28.9%
−10% to +10% baseline
On rallies (+10%+)
+14.4%
how they react when this stock rises
Holders' portfolio flow this Q
+2.8%
inflows — adds are organic
Sellers' portfolio flow this Q
-0.0%
Sellers' overall flow ~ flat.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-0.7%
Holder mid (any stock)
-1.7%
Holder rally (any stock)
-4.8%
Biggest decreases this quarter
FMR LLC−$24.8Mα-0.0STATE STREET CORP−$4.6Mα-0.2PRICE T ROWE ASSOCIATES INC /MD/−$3.6Mα-0.2HealthInvest Partners ABexited−$1.9MSoleus Capital Management, L.P.exited−$1.7MFIL Ltd−$1.6Mα+0.2JANE STREET GROUP, LLCexited−$1.4MY-Intercept (Hong Kong) Ltdexited−$1.0MDARK FOREST CAPITAL MANAGEMENT LPexited−$633KTrexquant Investment LPexited−$624K
New buyers this quarter
Top-5 holders · 41.6%
RA CAPITAL MANAGEMENT, L.P.--
T. Rowe Price Investment Management, Inc.--
Siren, L.L.C.--
Vestal Point Capital, LP--
Deep Track Capital, LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
RA CAPITAL MANAGEMENT, L.P.7.3MT. Rowe Price Investment Management, Inc.6.6MSiren, L.L.C.5.8MVestal Point Capital, LP5.4MDeep Track Capital, LP4.1MTPG GP A, LLC3.0MJANUS HENDERSON GROUP PLC3.3MRed Tree Management, LLC3.2MFMR LLC2.1MOmega Fund Management, LLC2.4M
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (3 analysts)$32.334860.0%
Last Year (8 analysts)$25.631780.0%
Current Price$21.75
Analyst Ratings
5
2
Buy: 5Hold: 2Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$8.98M
45 txns · 5 insiders · 492,202 sh
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$4.80M
1 txn · 1 insider · 2,500,000 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-18 | SELL | Mazumdar Claire | director, officer: Chief Executive Officer | 15,000 | $20.04 | $301K | $7.26M |
| 2026-05-15 | SELL | Cohlhepp Ryan | director, officer: President and COO | 12,500 | $20.29 | $254K | $3.89M |
| 2026-04-27 | SELL | Raben David | officer: Chief Medical Officer | 5,500 | $22.88 | $126K | $1.26M |
| 2026-04-21 | SELL | Hyep Ivan | officer: Chief Financial Officer | 9,200 | $23.00 | $212K | $3.34M |
| 2026-04-20 | SELL | Mazumdar Claire | director, officer: Chief Executive Officer | 15,000 | $23.61 | $354K | $8.55M |
| 2026-04-15 | SELL | Cohlhepp Ryan | director, officer: President and COO | 12,500 | $23.01 | $288K | $4.51M |
| 2026-03-25 | SELL | Raben David | officer: Chief Medical Officer | 5,500 | $18.95 | $104K | $1.05M |
| 2026-03-23 | SELL | Hyep Ivan | officer: Chief Financial Officer | 9,200 | $18.52 | $170K | $2.69M |
| 2026-03-20 | SELL | Mazumdar Claire | director, officer: Chief Executive Officer | 1,596 | $18.95 | $30K | $6.43M |
| 2026-03-19 | SELL | Mazumdar Claire | director, officer: Chief Executive Officer | 6,905 | $18.78 | $130K | $6.38M |
| 2026-03-18 | SELL | Mazumdar Claire | director, officer: Chief Executive Officer | 6,499 | $18.84 | $122K | $6.39M |
| 2026-03-16 | SELL | Cohlhepp Ryan | director, officer: President and COO | 12,500 | $19.66 | $246K | $3.94M |
| 2026-03-06 | SELL | Mazumdar Claire | director, officer: Chief Executive Officer | 3,817 | $18.75 | $72K | $6.36M |
| 2026-03-05 | SELL | Mazumdar Claire | director, officer: Chief Executive Officer | 1,786 | $18.74 | $33K | $6.36M |
| 2026-03-04 | SELL | Hyep Ivan | officer: Chief Financial Officer | 2,963 | $18.25 | $54K | $2.65M |
| 2026-03-04 | SELL | Mazumdar Claire | director, officer: Chief Executive Officer | 2,631 | $18.73 | $49K | $6.36M |
| 2026-03-04 | SELL | Raben David | officer: Chief Medical Officer | 16,300 | $18.52 | $302K | $1.02M |
| 2026-03-03 | SELL | Cohlhepp Ryan | director, officer: President and COO | 17,392 | $18.16 | $316K | $3.73M |
| 2026-03-03 | SELL | Hyep Ivan | officer: Chief Financial Officer | 13,555 | $18.22 | $247K | $2.65M |
| 2026-03-03 | SELL | Raben David | officer: Chief Medical Officer | 200 | $18.45 | $4K | $1.02M |
Order Flow (FINRA, ~3w lag)
7.9%retail-0.5pp
32.0%dark-2.7pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Bicara Therapeutics Inc.: Core IP Ownership Litigation and Imminent ATM Dilution Shadow Clinical Progress
Overall Risk
7/10
Fraud
3/10
Dilution
9/10
Insolvency
4/10
Earnings Overstated
3/10
Hidden Liabilities
6/10
Legal
8/10
Audit Warnings
2/10
Hidden Upside
5/10
Contextually Acceptable
6/10